

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

ASHKENAZI, et al.

Application Serial No. 09/909,088

Filed: July 18, 2001

For: SECRETED AND TRANSMEMBRANE
POLYPEPTIDES AND NUCLEIC
ACIDS ENCODING THE SAME



Examiner: Basi, Nirmal Singh

Art Unit: 1646

Attorney's Docket No. 39780-1618P2C79

Customer No. 35489

EXPRESS MAIL LABEL NO. EV 765 978 452 US
DATE MAILED: NOVEMBER 3, 2006

INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. §1.97

MAIL STOP — AMENDMENT

Commissioner for Patents
PO Box 1450
Alexandria, Virginia 22313-1450

Sir:

Listed below or on an attached Form PTO-1449 is information known to applicant(s). A copy of each listed publication and U.S. and foreign patent, except for pending U.S. applications, is being submitted herewith, along with a concise explanation of information in a foreign language, if any, pursuant to 37 C.F.R. §1.97-1.98.

Applicants respectfully request that the listed information be considered by the Examiner and be made of record in the above-identified application. If Form PTO-1449 is enclosed, the Examiner is requested to initial and return it in accordance with M.P.E.P. §609.

This statement is not intended to represent that a search has been made or that the information cited in the statement is, or is considered to be, material to patentability as defined in §1.56.

11/07/2006 RFEKADU1 00000035 081641 09909088
01 FC:1806 180.00 DA

This statement qualifies under 37 C.F.R. §1.97, subsection (b) because (check all that apply):

(1) It is being filed within 3 months of the application filing date and is other than a continued prosecution application under § 1.53(d)
-- OR --

(2) It is being filed within 3 months of entry of a national stage
-- OR --

(3) It is being filed before the mail date of the first Office Action on the merits
-- OR --

(4) It is being filed before the mailing of a first Office Action after the filing of a request for continued examination under § 1.114.

37 C.F.R. §1.97(c). If this statement is being filed after the latest of: (1) three months beyond the filing date of a national application; (2) three months beyond the date of entry of the national stage as set forth in §1.491 in an international application; or (3) the mailing date of a first Office action on the merits, but before the mailing date of the earlier of a final office action under §1.113 or a notice of allowance under §1.311, then:

a certification as specified in §1.97(e) is provided below; or

a fee of \$180.00 as set forth in §1.17(p) is authorized below, enclosed, or included with the payment of other papers filed together with this statement.

37 C.F.R. §1.97(d). If this statement is being filed after the mailing date of the earlier of a final office action under §1.113 or a notice of allowance under §1.311, but before payment of the issue fee, then:

A. a certification as specified in §1.97(e) is completed below; and

B. a petition under 37 C.F.R. §1.97(d) requesting consideration of this statement is submitted herewith; and

C. a fee of \$130.00 as set forth in §1.17(i)(1) is authorized below, enclosed, or included with the payment of other papers filed together with this statement.

Fee Authorization. The Commissioner is hereby authorized to charge the above-referenced fees of \$180.00 and charge any additional fees or credit any overpayment associated with this communication to Deposit Account No. 08-1641 (Attorney's Docket No. 39780-1618P2C79).

Respectfully submitted,

Dated: November 3, 2006

By: 
Ginger R. Dreger (Reg. No. 33,055)

HELLER EHRLICH LLP
275 Middlefield Road
Menlo Park, California 94025-3506
Telephone: (650) 324-7000
Facsimile: (650) 324-0638

Form PTO-1449 INFORMATION DISCLOSURE STATEMENT <i>(use several sheets if necessary)</i>				Attorney's Docket No. 39780-1618P2C79	Application Serial No. 09/909,088		
				Applicant(s) ASHKENAZI, et al.			
				Filing Date: July 18, 2001	Group Art Unit: 1646	NOV 03 2006 RIBBLE SEARCHED INDEXED MAILED	
U.S. PATENT DOCUMENTS							
Examiner Initials	Ref. No.	Date	Document No.	Name	Class	Subclass	Entered Date (if appropriate)
	1.	8/21/90	4,950,647	Robins et al.			10/4/88
	2.	7/15/97	5,648,376	Strobel et al.			1/19/95
	3.	9/1/98	5,801,193	Ojo-Amaize et al.			4/15/97
	4.	10/6/98	5,817,306	Haskill et al.			6/7/95
	5.	09/28/99	5,958,403	Storm, et al.			
FOREIGN PATENT DOCUMENTS							
Examiner Initials	Ref. No.	Date	Document No.	Name	Class	Subclass	Translation YES NO
OTHER DOCUMENTS <i>(including author, title, date, pertinent pages, etc.)</i>							
Examiner Initials	Ref. No.	Title					
	6.	Abolhassani, M., "Antibacterial effect of borage (<i>Echium amoenum</i>) on <i>Staphylococcus aureus</i> ," <i>Brazilian Journal of Infectious Diseases</i> 8:382-385 (2004).					
	8.	Amirghofran, Z. et al., "Echium amoenum stimulate of lymphocyte proliferation and inhibit fo humoral antibody synthesis," <i>Iran. J. Med. Sci.</i> 25:119-124 (2000).					
	8.	Chapoval, A. I. et al., "Combination chemotherapy and IL-15 administration induces permanent tumor regression in a mouse lung tumor model: NK and T cell-mediated effects antagonized by B cells," <i>J. Immunol.</i> 161:6977-6984 (1998).					
	9.	Fung-Leung, et al., "Tepoxalin, A Novel Immunomodulatory Compound, Synergizes with CSA In Suppression of Graft-Versus-Host Reaction and Allogeneic Skin Graft Rejection", <i>Transplantation</i> , 60:362-368 (1995).					
	10.	Gennari, R. et al., "Granulocyte macrophage colony-stimulating factor improves survival in two models of gut-derived sepsis by Improving gut barrier function and modulating bacterial clearance," <i>Annals of Surgery</i> 220:68-76 (1994).					
	11.	Grabstein, K.H. et al., "Cloning of a T cell growth factor that interacts with the beta chain of the interleukin-2 receptor," <i>Science</i> 264:965-968 (1994).					
	12.	Kasaihan, M.T. et al., "IL-21 limits NK cell responses and promotes antigen-specific T cell activation: a mediator of the transition from innate to adaptive immunity," <i>Immunity</i> 16:559-569 (2002).					
	13.	Kirchner, G.I. et al., "Pharmacokinetics of recombinant human interleukin-2 in advanced renal cell carcinoma patients following subcutaneous application," <i>Br. J. Clin. Pharmacol.</i> 46:5-10 (1998).					
	14.	Ma, H-L et al., "IL-21 activates both innate and adaptive immunity to generate potent antitumor responses that require perforin but are independent of INF- γ ," <i>J. Immunol.</i> 171:608-615 (2003).					
	15.	Naito, K. et al., "Macrophage factors which enhance the mixed leukocyte reaction initiated by dendritic cells," <i>J. Immunol.</i> 142:1834-1839 (1989).					
	16.	Nastala, C.L. et al., "Recombinant IL-12 administration induces tumor regression in association with IFN- γ production," <i>J. Immunol.</i> 153:1697-1706 (1994).					
	17.	Pahwa, R. et al., "Recombinant interleukin 2 therapy in severe combined immunodeficiency disease," <i>Proc. Natl. Acad. Sci. USA</i> 86:5069-5073 (1989).					
	18.	Patterson, S. et al., "Human invariant NKT cells are required for effective in vitro alloresponses," <i>J. Immunol.</i> 175:5087-5094 (2005).					

EXAMINER:	DATE CONSIDERED:
EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.	
*If an asterisk is placed beside the reference number, a copy is not provided because the reference was previously cited by or submitted to the PTO in a prior application that is identical in the statement and relied upon for an earlier filing date under 35 U.S.C. §120. 37 C.F.R. §1.98 (d). SV 2242531 v1	

EXAMINER:	DATE CONSIDERED:
EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.	
*If an asterisk is placed beside the reference number, a copy is not provided because the reference was previously cited by or submitted to the PTO in a prior application that is identical in the statement and relied upon for an earlier filing date under 35 U.S.C. §120. 37 C.F.R. §1.98 (d).	
SV 242531 v1	